Changing How We Treat Cancer, Beginning with Drug Approvals
Earlier this month, the FDA approved the drug Vitrakvi to treat a wide range of cancers. Andrew Norden, M.D., COTA’s Chief Medical Officer, discusses what this means for the future of cancer care and precision medicine.
CEO Corner: Mike Doyle’s First Month at COTA
New CEO Mike Doyle reflects on his first month at COTA, the impact of precision medicine in oncology, and the clinical value of real world evidence.
COTA Increases Breakthrough Capability, adds Chief Technology Officer
COTA Increases Breakthrough Capability, adds Chief Technology Officer